stockrowHalozyme Therapeutics, Inc.
HALO Healthcare Biotechnology
Halozyme Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 37.6% from fiscal 2024.
- Revenue
- +39.2%
- EPS
- +45.6%
- Free cash flow
- −58.6%
- Total debt
- +115.1%
Quarter to September 2026, against a year earlier
Follow HALO
Alert me
Halozyme Therapeutics, Inc. (HALO) Book value per share
Halozyme Therapeutics, Inc.'s book value per share at the end of fiscal 2025 was 0.4×, down 85.8% from 2.9× in fiscal 2024. At the end of the quarter to 30 September 2026 it was −0.5×. Over the past ten years it has ranged from −0.3× (fiscal 2016) to 2.9× (fiscal 2024); the current reading is higher than 27% of that period. Halozyme Therapeutics, Inc. ranks 558th of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 0.4× | (85.80%) |
| FY2024 | 2.9× | 351.53% |
| FY2023 | 0.6× | (48.80%) |
| FY2022 | 1.2× | (11.39%) |
| FY2021 | 1.4× | 26.27% |
| FY2020 | 1.1× | 74.43% |
| FY2019 | 0.6× | (63.32%) |
| FY2018 | 1.7× | 13.47% |
| FY2017 | 1.5× | — |
| FY2016 | −0.3× | — |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Sep 2026 | −0.5× | — |
| Jun 2026 | 1.2× | (34.16%) |
| Mar 2026 | 1.9× | 356.44% |
| Dec 2025 | 0.4× | (90.53%) |
| 43 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| JAZZ Jazz Pharmaceuticals PLC compare | 64.8× |
| BMRN BioMarin Pharmaceutical Inc. compare | 32.3× |
| ASND Ascendis Pharma A/S compare | 26.0× |
| KYMR Kymera Therapeutics, Inc. compare | 16.1× |
| TECH Bio-Techne Corp compare | 13.5× |
| EXEL Exelixis, Inc. compare | 7.4× |
| SMMT Summit Therapeutics PLC compare | 0.8× |
| HALO Halozyme Therapeutics, Inc. | −0.5× |
| BBIO BridgeBio Pharma, Inc. compare | −8.4× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on HALO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement